{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:09:41Z","timestamp":1793196581104,"version":"4.5.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,12,27]],"date-time":"2017-12-27T00:00:00Z","timestamp":1514332800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"National Nature Science Foundation","award":["81330012"],"award-info":[{"award-number":["81330012"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s10620-017-4866-6","type":"journal-article","created":{"date-parts":[[2017,12,27]],"date-time":"2017-12-27T07:50:52Z","timestamp":1514361052000},"page":"302-311","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Vonoprazan: A Novel and Potent Alternative in the\u00a0Treatment of Acid-Related Diseases"],"prefix":"10.1007","volume":"63","author":[{"given":"Xiaoxiao","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanguo","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iqtida Ahmed","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0575-0399","authenticated-orcid":false,"given":"Yan-Qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,27]]},"reference":[{"key":"4866_CR1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1586\/ecp.09.8","volume":"2","author":"A Mejia","year":"2009","unstructured":"Mejia A, Kraft WK. Acid peptic diseases: pharmacological approach to treatment. Expert Rev Clin Pharmacol. 2009;2:295\u2013314.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"4866_CR2","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0005-2736(73)90035-7","volume":"307","author":"AL Ganser","year":"1973","unstructured":"Ganser AL, Forte JG. K+-stimulated ATPase in purified microsomes of bullfrog oxyntic cells. Biochim Biophys Acta.. 1973;307:169\u2013180.","journal-title":"Biochim Biophys Acta."},{"key":"4866_CR3","first-page":"42","volume":"145","author":"P Malfertheiner","year":"2003","unstructured":"Malfertheiner P. Guidelines for the diagnosis and treatment of H. pylori infection. MMW Fortschr Med. 2003;145:42\u201345.","journal-title":"MMW Fortschr Med"},{"key":"4866_CR4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","volume":"66","author":"P Malfertheiner","year":"2017","unstructured":"Malfertheiner P, Megraud F, O\u2019Morain CA, et al. Management of Helicobacter pylori infection\u2014the Maastricht V\/Florence Consensus Report. Gut. 2017;66:6\u201330.","journal-title":"Gut"},{"key":"4866_CR5","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1053\/j.gastro.2016.04.006","volume":"151","author":"CA Fallone","year":"2016","unstructured":"Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151:e14.","journal-title":"Gastroenterology"},{"key":"4866_CR6","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/apt.13325","volume":"42","author":"Y Sakurai","year":"2015","unstructured":"Sakurai Y, Mori Y, Okamoto H, et al. Acid-inhibitory effects of vonoprazan 20\u00a0mg compared with esomeprazole 20\u00a0mg or rabeprazole 10\u00a0mg in healthy adult male subjects\u2013a randomised open-label cross-over study. Aliment Pharmacol Ther. 2015;42:719\u2013730.","journal-title":"Aliment Pharmacol Ther"},{"key":"4866_CR7","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1007\/s10620-010-1209-2","volume":"55","author":"WD Chey","year":"2010","unstructured":"Chey WD, Mody RR, Izat E. Patient and physician satisfaction with proton pump inhibitors (PPIs): are there opportunities for improvement? Dig Dis Sci. 2010;55:3415\u20133422.","journal-title":"Dig Dis Sci"},{"key":"4866_CR8","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1046\/j.1365-2036.2000.00837.x","volume":"14","author":"G Sachs","year":"2000","unstructured":"Sachs G, Shin JM, Munson K, et al. Review article: the control of gastric acid and Helicobacter pylori eradication. Aliment. Pharmacol. Ther.. 2000;14:1383\u20131401.","journal-title":"Aliment. Pharmacol. Ther."},{"key":"4866_CR9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/1087057111421004","volume":"17","author":"M Kondo","year":"2012","unstructured":"Kondo M, Kawamoto M, Hasuoka A, Kajino M, Inatomi N, Tarui N. High-throughput screening of potassium-competitive acid blockers. J Biomol Screen. 2012;17:177\u2013182.","journal-title":"J Biomol Screen"},{"key":"4866_CR10","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40265-015-0368-z","volume":"75","author":"KP Garnock-Jones","year":"2015","unstructured":"Garnock-Jones KP. Vonoprazan: first global approval. Drugs. 2015;75:439\u2013443.","journal-title":"Drugs"},{"key":"4866_CR11","doi-asserted-by":"crossref","first-page":"5545","DOI":"10.1016\/S0021-9258(18)83580-3","volume":"264","author":"DJ Keeling","year":"1989","unstructured":"Keeling DJ, Taylor AG, Schudt C. The binding of a K+ competitive ligand, 2-methyl,8-(phenylmethoxy)imidazo(1,2-a)pyridine 3-acetonitrile, to the gastric (H+\u00a0+\u00a0K+)-ATPase. J Biol Chem. 1989;264:5545\u20135551.","journal-title":"J Biol Chem"},{"key":"4866_CR12","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/apt.13414","volume":"42","author":"DR Scott","year":"2015","unstructured":"Scott DR, Munson KB, Marcus EA, Lambrecht NW, Sachs G. The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+-ATPase. Aliment Pharmacol Ther. 2015;42:1315\u20131326.","journal-title":"Aliment Pharmacol Ther"},{"key":"4866_CR13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5056\/jnm.2013.19.1.25","volume":"19","author":"JM Shin","year":"2013","unstructured":"Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013;19:25\u201335.","journal-title":"J Neurogastroenterol Motil"},{"key":"4866_CR14","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1124\/jpet.111.185314","volume":"339","author":"JM Shin","year":"2011","unstructured":"Shin JM, Inatomi N, Munson K, et al. Characterization of a novel potassium-competitive acid blocker of the gastric H, K-ATPase, 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438). J Pharmacol Exp Ther. 2011;339:412\u2013420.","journal-title":"J Pharmacol Exp Ther"},{"key":"4866_CR15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1124\/jpet.110.170274","volume":"335","author":"Y Hori","year":"2010","unstructured":"Hori Y, Imanishi A, Matsukawa J, et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther. 2010;335:231\u2013238.","journal-title":"J Pharmacol Exp Ther"},{"key":"4866_CR16","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/apt.13121","volume":"41","author":"H Jenkins","year":"2015","unstructured":"Jenkins H, Sakurai Y, Nishimura A, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2015;41:636\u2013648.","journal-title":"Aliment Pharmacol Ther"},{"key":"4866_CR17","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1021\/jm300318t","volume":"55","author":"Y Arikawa","year":"2012","unstructured":"Arikawa Y, Nishida H, Kurasawa O, et al. Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamin e fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB). J Med Chem. 2012;55:4446\u20134456.","journal-title":"J Med Chem"},{"key":"4866_CR18","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1038\/ctg.2015.18","volume":"6","author":"Y Sakurai","year":"2015","unstructured":"Sakurai Y, Nishimura A, Kennedy G, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single rising TAK-438 (vonoprazan) doses in healthy male Japanese\/non-Japanese subjects. Clin Transl Gastroenterol. 2015;6:e94.","journal-title":"Clin Transl Gastroenterol"},{"key":"4866_CR19","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pharmthera.2016.08.001","volume":"168","author":"N Inatomi","year":"2016","unstructured":"Inatomi N, Matsukawa J, Sakurai Y, Otake K. Potassium-competitive acid blockers: advanced therapeutic option for acid-related diseases. Pharmacol Ther. 2016;168:12\u201322.","journal-title":"Pharmacol Ther"},{"key":"4866_CR20","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/apt.13588","volume":"43","author":"T Kagami","year":"2016","unstructured":"Kagami T, Sahara S, Ichikawa H, et al. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype. Aliment Pharmacol Ther. 2016;43:1048\u20131059.","journal-title":"Aliment Pharmacol Ther"},{"key":"4866_CR21","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/ajg.2012.444","volume":"108","author":"PO Katz","year":"2013","unstructured":"Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol.. 2013;108:308\u2013328. (quiz 329).","journal-title":"Am J Gastroenterol."},{"key":"4866_CR22","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1136\/gutjnl-2012-304269","volume":"63","author":"HB El-Serag","year":"2014","unstructured":"El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63:871\u2013880.","journal-title":"Gut"},{"key":"4866_CR23","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/apt.13331","volume":"42","author":"K Ashida","year":"2015","unstructured":"Ashida K, Sakurai Y, Nishimura A, et al. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther. 2015;42:685\u2013695.","journal-title":"Aliment Pharmacol Ther"},{"key":"4866_CR24","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/apt.13461","volume":"43","author":"K Ashida","year":"2016","unstructured":"Ashida K, Sakurai Y, Hori T, et al. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther. 2016;43:240\u2013251.","journal-title":"Aliment Pharmacol Ther"},{"key":"4866_CR25","doi-asserted-by":"crossref","first-page":"S475","DOI":"10.1016\/S0016-5085(16)31635-3","volume":"150","author":"K Iwakiri","year":"2016","unstructured":"Iwakiri K, Umegaki E, Hiramatsu N, et al. Su1119 A Phase 3, randomized, double-blind, multicenter study to evaluate the dose-response relationships of acid-inhibitory effect of vonoprazan (20\u00a0mg, 40\u00a0mg) in patients with proton pump inhibitor-resistant erosive esophagitis [Abstract]. Gastroenterology. 2016;150:S475\u2013S475.","journal-title":"Gastroenterology"},{"key":"4866_CR26","doi-asserted-by":"crossref","first-page":"S475","DOI":"10.1016\/S0016-5085(16)31636-5","volume":"150","author":"Y Hanada","year":"2016","unstructured":"Hanada Y, Hoshino S, Hoshikawa Y, et al. Su1120 efficacy of vonoprazan on PPI-resistant reflux esophagitis [Abstract]. Gastroenterology. 2016;150:S475\u2013S475.","journal-title":"Gastroenterology"},{"key":"4866_CR27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/jgh.13355","volume":"31","author":"T Koike","year":"2016","unstructured":"Koike T, Saito M, Kikuchi H, et al. Vonoprazan reduces the GERD symptoms in the symptom index positive PPI-refractory NERD. J Gastroenterol Hepatol. 2016;31:21.","journal-title":"J Gastroenterol Hepatol"},{"key":"4866_CR28","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3892\/br.2016.828","volume":"6","author":"D Asaoka","year":"2017","unstructured":"Asaoka D, Nagahara A, Hojo M, et al. Efficacy of a potassium-competitive acid blocker for improving symptoms in patients with reflux esophagitis, non-erosive reflux disease, and functional dyspepsia. Biomed Rep. 2017;6:175\u2013180.","journal-title":"Biomed Rep"},{"key":"4866_CR29","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/den.12705","volume":"29","author":"D Maruoka","year":"2017","unstructured":"Maruoka D, Arai M, Kasamatsu S, et al. Vonoprazan is superior to proton pump inhibitors in healing artificial ulcers of the stomach post-endoscopic submucosal dissection: A propensity score-matching analysis. Dig Endosc. 2017;29:57\u201364.","journal-title":"Dig Endosc"},{"key":"4866_CR30","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/apt.13747","volume":"44","author":"T Kagawa","year":"2016","unstructured":"Kagawa T, Iwamuro M, Ishikawa S, et al. Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers. Aliment Pharmacol Ther. 2016;44:583\u2013591.","journal-title":"Aliment Pharmacol Ther"},{"key":"4866_CR31","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/den.12857","volume":"29","author":"I Tsuchiya","year":"2017","unstructured":"Tsuchiya I, Kato Y, Tanida E, et al. Effect of vonoprazan on the treatment of artificial gastric ulcers after endoscopic submucosal dissection: prospective randomized controlled trial. Dig Endosc. 2017;29:576\u2013583.","journal-title":"Dig Endosc"},{"key":"4866_CR32","doi-asserted-by":"crossref","first-page":"716","DOI":"10.4253\/wjge.v8.i19.716","volume":"8","author":"K Takahashi","year":"2016","unstructured":"Takahashi K, Sato Y, Kohisa J, et al. Vonoprazan 20\u00a0mg vs lansoprazole 30\u00a0mg for endoscopic submucosal dissection-induced gastric ulcers. World J Gastrointest Endosc. 2016;8:716\u2013722.","journal-title":"World J Gastrointest Endosc"},{"key":"4866_CR33","first-page":"291","volume":"31","author":"K Hiroyuki","year":"2016","unstructured":"Hiroyuki K, Hiroya U, Akihito N, et al. # 1505 Vonoprazan versus rabeprazole for the healing effect of gastric ulcers after endoscopic submucosal dissection: a prospective randomized controlled trial. J Gastroenterol Hepatol. 2016;31:291.","journal-title":"J Gastroenterol Hepatol"},{"key":"4866_CR34","doi-asserted-by":"crossref","first-page":"S739","DOI":"10.1016\/S0016-5085(14)62677-9","volume":"146","author":"Y Mizokami","year":"2014","unstructured":"Mizokami Y, Ashida K, Soen S, et al. Tu1054 TAK-438 versus lansoprazole 15\u00a0mg for secondary prevention of peptic ulcers associated with non-steroidal anti-inflammatory drug (NSAID) therapy: results of a Phase 3 trial. Gastroenterology. 2014;146:S739.","journal-title":"Gastroenterology"},{"key":"4866_CR35","doi-asserted-by":"crossref","first-page":"S739","DOI":"10.1016\/S0016-5085(14)62678-0","volume":"146","author":"T Kawai","year":"2014","unstructured":"Kawai T, Ashida K, Mizokami Y, et al. Tu1055 TAK-438 versus lansoprazole 15\u00a0mg for secondary prevention of peptic ulcers associated with low-dose aspirin therapy: results of a Phase 3 trial [Abstract]. Gastroenterology. 2014;146:S739.","journal-title":"Gastroenterology"},{"key":"4866_CR36","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40261-016-0455-2","volume":"37","author":"Y Sakurai","year":"2017","unstructured":"Sakurai Y, Shiino M, Horii S, et al. Pharmacokinetic drug\u2013drug interactions between vonoprazan and low-dose aspirin or nonsteroidal anti-inflammatory drugs: a Phase 2, open-label, study in healthy Japanese men. Clin Drug Invest. 2017;37:39\u201349.","journal-title":"Clin Drug Invest"},{"key":"4866_CR37","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/apt.13876","volume":"45","author":"H Miwa","year":"2017","unstructured":"Miwa H, Uedo N, Watari J, et al. Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers\u2014results from two phase 3, non-inferiority randomised controlled trials. Aliment Pharmacol Ther. 2017;45:240\u2013252.","journal-title":"Aliment Pharmacol Ther"},{"key":"4866_CR38","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/ajg.2016.182","volume":"111","author":"S Suzuki","year":"2016","unstructured":"Suzuki S, Gotoda T, Kusano C, Iwatsuka K, Moriyama M. The efficacy and tolerability of a triple therapy containing a potassium-competitive acid blocker compared with a 7-day PPI-based low-dose clarithromycin triple therapy. Am J Gastroenterol. 2016;111:949\u2013956.","journal-title":"Am J Gastroenterol"},{"key":"4866_CR39","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.kjms.2016.04.009","volume":"32","author":"S Shinozaki","year":"2016","unstructured":"Shinozaki S, Nomoto H, Kondo Y, et al. Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori. Kaohsiung J Med Sci. 2016;32:255\u2013260.","journal-title":"Kaohsiung J Med Sci"},{"key":"4866_CR40","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/1751-2980.12398","volume":"17","author":"S Shichijo","year":"2016","unstructured":"Shichijo S, Hirata Y, Niikura R, et al. Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: a multicenter retrospective study in clinical practice. J Dig Dis. 2016;17:670\u2013675.","journal-title":"J Dig Dis"},{"key":"4866_CR41","doi-asserted-by":"crossref","first-page":"283","DOI":"10.15403\/jgld.2014.1121.253.7hp","volume":"25","author":"H Noda","year":"2016","unstructured":"Noda H, Noguchi S, Yoshimine T, et al. A novel potassium-competitive acid blocker improves the efficacy of clarithromycin-containing 7-day triple therapy against Helicobacter pylori. J Gastrointestin Liver Dis. 2016;25:283\u2013288.","journal-title":"J Gastrointestin Liver Dis"},{"key":"4866_CR42","doi-asserted-by":"crossref","first-page":"550","DOI":"10.4292\/wjgpt.v7.i4.550","volume":"7","author":"S Yamada","year":"2016","unstructured":"Yamada S, Kawakami T, Nakatsugawa Y, et al. Usefulness of vonoprazan, a potassium ion-competitive acid blocker, for primary eradication of Helicobacter pylori. World J Gastrointest Pharmacol Ther. 2016;7:550\u2013555.","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"4866_CR43","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1136\/gutjnl-2015-311304","volume":"65","author":"K Murakami","year":"2016","unstructured":"Murakami K, Sakurai Y, Shiino M, Funao N, Nishinura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut. 2016;65:1439\u20131446.","journal-title":"Gut"},{"key":"4866_CR44","doi-asserted-by":"crossref","first-page":"S1269","DOI":"10.1016\/S0016-5085(16)34288-3","volume":"150","author":"M Maruyama","year":"2016","unstructured":"Maruyama M, Kubota D, Miyajima M, et al. Tu2083 A randomized controlled trial comparing the first-line eradication rate using vonoprazan or PPI for Helicobacter pylori infectious gastritis [Abstract]. Gastroenterology. 2016;150:S1269\u2013S1269.","journal-title":"Gastroenterology"},{"key":"4866_CR45","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1007\/s10620-016-4305-0","volume":"61","author":"H Matsumoto","year":"2016","unstructured":"Matsumoto H, Shiotani A, Katsumata R, Fujita M, Nakato R, Murao T. Helicobacter pylori Eradication with proton pump inhibitors or potassium-competitive acid blockers: the effect of clarithromycin resistance. Dig Dis Sci. 2016;61:3215\u20133220.","journal-title":"Dig Dis Sci"},{"key":"4866_CR46","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s12325-016-0374-x","volume":"33","author":"Y Sakurai","year":"2016","unstructured":"Sakurai Y, Shiino M, Okamoto H, Nishimura A, Nakamura K, Hasegawa S. Pharmacokinetics and safety of triple therapy with vonoprazan, amoxicillin, and clarithromycin or metronidazole: a Phase 1, open-label, randomized, crossover study. Adv Ther. 2016;33:1519\u20131535.","journal-title":"Adv Ther"},{"key":"4866_CR47","first-page":"61","volume":"31","author":"T Yamasaki","year":"2016","unstructured":"Yamasaki T, Owari M, Amano Y, et al. High dose CAM with vonoprazan (P-CAB) plus AMX regimen is the strongest H. pylori eradication triple therapy regimens to improve success rate of CAM based regimens. J Gastroenterol Hepatol. 2016;31:61.","journal-title":"J Gastroenterol Hepatol"},{"key":"4866_CR48","first-page":"384","volume":"66","author":"DY Graham","year":"2017","unstructured":"Graham DY. Vonoprazan Helicobacter pylori eradication therapy: ethical and interpretation issues. Gut. 2017;66:384\u2013386.","journal-title":"Gut"},{"key":"4866_CR49","first-page":"S877","volume":"150","author":"T Furuta","year":"2016","unstructured":"Furuta T, Shu S, Ichikawa H, et al. Tu1333 dual therapy with vonoprazan and amoxicillin is as effective as standard PPI-based triple therapy with amoxicillin and clarithromycin or metronidazole in Japan [Abstract]. Gastroenterology. 2016;150:S877\u2013S877.","journal-title":"Gastroenterology"},{"key":"4866_CR50","first-page":"67","volume":"31","author":"Yu Sato","year":"2016","unstructured":"Sato Yu, Yamamoto K, Onishi Y, et al. Efficacy of the vonoprazan (VPZ)-based second line therapy for Helicobacter pylori (HP) eradication. J Gastroenterol Hepatol. 2016;31:67.","journal-title":"J Gastroenterol Hepatol"},{"key":"4866_CR51","doi-asserted-by":"crossref","first-page":"S447","DOI":"10.1016\/S0016-5085(16)31555-4","volume":"150","author":"K Okimoto","year":"2016","unstructured":"Okimoto K, Arai M, Kasamatsu S, et al. Su1027 efficacy of sitafloxacin-based triple therapy for eradication-refractory Helicobacter pylori and salvage therapy with the new potassium-competitive acid blocker vonoprazan [Abstract]. Gastroenterology. 2016;150:S447\u2013S447.","journal-title":"Gastroenterology"},{"key":"4866_CR52","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.dld.2016.02.021","volume":"48","author":"K Kawashima","year":"2016","unstructured":"Kawashima K, Ishihara S, Kinoshita Y. Successful eradication of Helicobacter pylori infection with vonoprazan-based triple therapy after failure of PPI-based triple therapy. Dig Liver Dis. 2016;48:688\u2013689.","journal-title":"Dig Liver Dis"},{"key":"4866_CR53","doi-asserted-by":"crossref","first-page":"e12374","DOI":"10.1111\/hel.12374","volume":"22","author":"S Ono","year":"2017","unstructured":"Ono S, Kato M, Nakagawa S, Mabe K, Sakamoto N. Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin. Helicobacter. 2017;22:e12374.","journal-title":"Helicobacter"},{"key":"4866_CR54","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/apt.14130","volume":"46","author":"YS Jung","year":"2017","unstructured":"Jung YS, Kim EH, Park CH. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther. 2017;46:106\u2013114. https:\/\/doi.org\/10.1111\/apt.14130 .","journal-title":"Aliment Pharmacol Ther"},{"key":"4866_CR55","doi-asserted-by":"publisher","unstructured":"Dong SQ, Singh TP, Wei X, Yao H, Wang HL. A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: is superiority an illusion? Helicobacter. 2017;22. https:\/\/doi.org\/10.1111\/hel.12438 .","DOI":"10.1111\/hel.12438"},{"key":"4866_CR56","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/apt.14198","volume":"46","author":"AG Fraser","year":"2017","unstructured":"Fraser AG. Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori. Aliment Pharmacol Ther. 2017;46:550\u2013551.","journal-title":"Aliment Pharmacol Ther"},{"key":"4866_CR57","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/apt.14206","volume":"46","author":"YS Jung","year":"2017","unstructured":"Jung YS, Kim EH, Park CH. Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori-authors\u2019 reply. Aliment Pharmacol Ther. 2017;46:551\u2013552.","journal-title":"Aliment Pharmacol Ther"},{"key":"4866_CR58","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1517\/13543784.14.4.411","volume":"14","author":"P Me","year":"2005","unstructured":"Me P, Dj K. Novel approaches to the pharmacological blockade of gastric acid secretion. Expert Opin Invest Drugs. 2005;14:411\u2013421.","journal-title":"Expert Opin Invest Drugs"},{"key":"4866_CR59","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.cgh.2007.08.014","volume":"5","author":"PJ Kahrilas","year":"2007","unstructured":"Kahrilas PJ, Dent J, Lauritsen K, Malfertheiner P, Denison H, Franz\u00e9n S. A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol. 2007;5:1385\u20131391.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4866_CR60","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/1346-8138.13187","volume":"43","author":"K Kamiya","year":"2016","unstructured":"Kamiya K, Nishio E, Horio A, Tokura Y. Erythema multiforme caused by triple therapy with amoxicillin, clarithromycin and vonoprazan for Helicobacter pylori. J Dermatol. 2016;43:340\u2013341.","journal-title":"J Dermatol"},{"key":"4866_CR61","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s40265-017-0712-6","volume":"77","author":"DA Johnson","year":"2017","unstructured":"Johnson DA, Katz PO, Armstrong D, et al. The safety of appropriate use of over-the-counter proton pump inhibitors: an evidence-based review and Delphi consensus. Drugs. 2017;77:547\u2013561.","journal-title":"Drugs"},{"key":"4866_CR62","doi-asserted-by":"crossref","first-page":"30590","DOI":"10.1074\/jbc.M114.584623","volume":"289","author":"K Abe","year":"2014","unstructured":"Abe K, Tani K, Fujiyoshi Y. Systematic comparison of molecular conformations of H+, K+-ATPase reveals an important contribution of the A-M2 linker for the luminal gating. J Biol Chem. 2014;289:30590\u201330601.","journal-title":"J Biol Chem"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-017-4866-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-017-4866-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-017-4866-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T05:15:51Z","timestamp":1660194951000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-017-4866-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,27]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["4866"],"URL":"https:\/\/doi.org\/10.1007\/s10620-017-4866-6","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,27]]}}}